Hany Elmariah, Salman Otoukesh, Ambuj Kumar, Haris Ali, Shukaib Arslan, Geoffrey Shouse, Hoda Pourhassan, Taiga Nishihori, Rawan Faramand, Asmita Mishra, Farhad Khimani, Hugo Fernandez, Aleksandr Lazaryan, Michael Nieder, Lia Perez, Hien Liu, Ryotaro Nakamura, Joseph Pidala, Guido Marcucci, Stephen J Forman, Claudio Anasetti, Frederick Locke, Nelli Bejanyan, Monzr M Al Malki
Graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF) for allogeneic haploidentical donor (haplo) hematopoietic cell transplantation (HCT) results in comparable outcomes to matched unrelated donor HCT. A phase II study from the Moffitt Cancer Center substituting sirolimus (Siro) for Tac in this prophylactic regimen reported comparable rates of grade II-IV acute GVHD (aGVHD). Many centers have substituted Siro for Tac in this setting based on a preferable side effect profile, although comparative data are limited...
February 2024: Transplantation and cellular therapy